SOX4-SMARCA4 complex promotes glycolysis-dependent TNBC cell growth through transcriptional regulation of Hexokinase 2.

Autor: Khanna P; Department of Radiation Oncology, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA., Mehta R; Department of Radiation Oncology, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA., Mehta GA; Department of Radiation Oncology, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA., Bhatt V; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.; Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901.; Department of Chemical Biology, Rutgers Ernest Mario School of Pharmacy, Piscataway, New Jersey 08854., Guo JY; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.; Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey 08901.; Department of Chemical Biology, Rutgers Ernest Mario School of Pharmacy, Piscataway, New Jersey 08854., Gatza ML; Department of Radiation Oncology, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2023 Sep 13. Date of Electronic Publication: 2023 Sep 13.

SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2.

Autor: Mehta GA; Department of Radiation Oncology, Robert Wood Johnson Medical School, New Brunswick, NJ, USA.; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Angus SP; Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA., Khella CA; Department of Radiation Oncology, Robert Wood Johnson Medical School, New Brunswick, NJ, USA.; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Tong K; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Genetics, Human Genetics Institute of New Jersey, Rutgers, The State University of New Jersey, Piscataway, NJ, USA., Khanna P; Department of Radiation Oncology, Robert Wood Johnson Medical School, New Brunswick, NJ, USA.; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Dixon SAH; Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA., Verzi MP; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.; Department of Genetics, Human Genetics Institute of New Jersey, Rutgers, The State University of New Jersey, Piscataway, NJ, USA., Johnson GL; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA., Gatza ML; Department of Radiation Oncology, Robert Wood Johnson Medical School, New Brunswick, NJ, USA. Michael.gatza@cinj.rutgers.edu.; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. Michael.gatza@cinj.rutgers.edu.

Publikováno v: NPJ breast cancer [NPJ Breast Cancer] 2021 Apr 09; Vol. 7 (1), pp. 40. Date of Electronic Publication: 2021 Apr 09.

Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.

Autor: Karagoz K; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States; Department of Radiation Oncology, Robert Wood Johnson Medical School, United States; Rutgers, The State University of New Jersey, New Brunswick NJ, United States., Mehta GA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States; Department of Radiation Oncology, Robert Wood Johnson Medical School, United States; Rutgers, The State University of New Jersey, New Brunswick NJ, United States., Khella CA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States; Department of Radiation Oncology, Robert Wood Johnson Medical School, United States; Rutgers, The State University of New Jersey, New Brunswick NJ, United States., Khanna P; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States; Department of Radiation Oncology, Robert Wood Johnson Medical School, United States; Rutgers, The State University of New Jersey, New Brunswick NJ, United States., Gatza ML; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States; Department of Radiation Oncology, Robert Wood Johnson Medical School, United States; Rutgers, The State University of New Jersey, New Brunswick NJ, United States. Electronic address: Michael.gatza@cinj.rutgers.edu.

Publikováno v: EBioMedicine [EBioMedicine] 2019 Dec; Vol. 50, pp. 191-202. Date of Electronic Publication: 2019 Nov 22.

Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.

Autor: Thomas A; Section of Hematology and Oncology, Department of Internal Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.; Wake Forest Comprehensive Cancer Center, Winston-Salem, NC, USA., Routh ED; Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA., Pullikuth A; Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA., Jin G; Wake Forest Comprehensive Cancer Center, Winston-Salem, NC, USA.; Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA., Su J; Division of Radiologic Sciences and Center for Bioinformatics and Systems Biology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, USA., Chou JW; Wake Forest Comprehensive Cancer Center, Winston-Salem, NC, USA.; Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA., Hoadley KA; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Print C; Department of Molecular Medicine and Pathology and Maurice Wilkins Institute, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand., Knowlton N; Department of Molecular Medicine and Pathology and Maurice Wilkins Institute, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand., Black MA; Department of Biochemistry, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand., Demaria S; Department of Radiation Oncology and Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA., Wang E; Department of Tumor Biology, Immunology and Therapy, Division of Translational Medicine, Sidra Medical and Research Center, Doha, Qatar., Bedognetti D; Department of Tumor Biology, Immunology and Therapy, Division of Translational Medicine, Sidra Medical and Research Center, Doha, Qatar., Jones WD; EA Genomics, Division of Q Solutions, Morrisville, NC., Mehta GA; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Gatza ML; Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Perou CM; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Page DB; Department of Medicine, Providence Cancer Center, Earle A. Chiles Research Institute, Portland, OR, USA., Triozzi P; Section of Hematology and Oncology, Department of Internal Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.; Wake Forest Comprehensive Cancer Center, Winston-Salem, NC, USA., Miller LD; Wake Forest Comprehensive Cancer Center, Winston-Salem, NC, USA.; Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Publikováno v: Oncoimmunology [Oncoimmunology] 2018 Jul 30; Vol. 7 (10), pp. e1490854. Date of Electronic Publication: 2018 Jul 30 (Print Publication: 2018).